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ABSTRACT OF THE DISSERTATION 
Survivin: Regulation by YY1 and Role in Pancreatic Cancer Combination Therapy 
by 
Nicholas R. Galloway 
Doctor of Philosophy, Graduate Program in Biochemistry 
Loma Linda University, March 2014 
Dr. Nathan Wall, Chairperson 
 
Despite significant clinical and basic science advancements, cancer remains a 
devastating disease that affects people of all ages, races, and background.  Survivin, the 
fourth most common transcript found in cancer cells, is a protein that is thought to be 
involved in the enhanced proliferation, survival, and metastasis of cancer cells.  
Therefore understanding how this gene is regulated is potentially of vital importance to 
improving cancer management and therapy.   Our work has identified a novel 
transcriptional regulator of survivin called Yin Yang 1 (YY1).  YY1 is a transcription 
factor that has been observed to activate some gene promoters and repress others, and it is 
gaining increasing interest as a target of cancer therapy.  Our work shows for the first 
time that YY1 is a repressor of survivin transcription and can do so by physically 
interacting with the survivin promoter.  Furthermore, YY1 appears to contribute to basal 
survivin transcriptional activity, indicating that disruption of its binding may in part 
contribute to survivin overexpression after cellular stress events including chemo- and 
radiotherapy.  It is also important to use gained mechanistic understandings of cancer 
initiation and progression to design logical new approaches to cancer therapy. Pancreatic 
cancer is one of the most deadly forms of cancer known, and survivin expression has 
been observed to be an important factor in pancreatic cancer aggressiveness or resistance 
 xii 
to therapy.  Therefore survivin downregulation may represent an important means of 
gaining improved treatment efficacy in pancreatic cancer.  Using combined gemcitabine 
and proton radiation therapy, we show that downregulation of survivin and its family 
member X-linked IAP may lead improved cell death following treatment, particularly 
when gemcitabine therapy is instituted prior to proton radiotherapy.  
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CHAPTER ONE 
INTRODUCTION 
 
Cancer Facts and Figures 
Cancer is one of the most devastating diseases in the world, and one that has 
touched the lives of nearly every family and individual in the United States.  The 
National Cancer Institute estimates that in January 2012 there were an estimated 13.7 
million individuals living in the United States that had a personal history of cancer.  The 
projected number of new cases of cancer in 2013 is 1,660,290.  It is the second most 
common cause of death, accounting for approximately 1 in 4 deaths in the United States.  
Furthermore, 580,350 individuals are projected to die as a result of cancer in 2013.  
Figure 1 illustrates the death rates for males (A) and females (B) from 1930-2009.  
Fortunately, progress has been made in detection and treatment of cancer, resulting in an 
increase in overall 5-year cancer survival of 68% between 2001-2008 up from 49% 
between 1975-1977.   
Cancer also imposes an enormous financial burden on the United States.  The 
National Institutes of Health estimate the overall cost of all cancers in 2008 to be $201.5 
billion: $77.4 billion for direct medical costs and $124 billion for indirect costs related to 
premature death and lost productivity1. 
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Figure 1.  Age-adjusted cancer death rates, 1930-2009.  Upper panel shows values for 
males, lower panel shows values for females.  Adapted from American Cancer Society 
Cancer Facts and Figures 2013 1. 
3 
The leading cause of cancer death in 2013 was lung and bronchus cancer for both 
men and women.  However, prostate and breast cancer continue to have the highest 
incidence in men and women, respectively.   Pancreatic cancer, a disease of particular 
importance to the chapter 3 of this dissertation, has presented a particularly large 
challenge to cancer biologists and oncologists, as it continues to be one of the most lethal 
cancers.  Pancreatic cancer will cause an estimated 38,460 deaths in 2013, occuring 
almost equally in men and women (Figure 2).  From 2001-2007, the 5 year survival rate 
for pancreatic cancer (all stages) was 6%.  Since 2004, the overall incidence of pancreatic 
cancer has been increasing by 1.5% per year.    
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Figure 2.  Leading new cancer cases and deaths-2013.  The estimated number of new 
cases for males vs. females is shown of the left, and esimates for cancer deaths in males 
vs. females is shown on the right.  Adapted from American Cancer Society Cancer Facts 
and Figures 2013 1. 
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The figures shown above illustrate that some of the advances made in clinical and 
basic science are indeed making an impact.  However, they simultaneously depict a 
disease in which scientists may be winning battles, but are clearly still losing the war.  
This dissertation will explain work that has been done regarding the regulation of a 
dysregulated cancer gene called survivin that may very well be a key to moving past 
incremental, small victories in the fight against cancer onto large changes in how cancer 
of all types is treated, and hopefully one day eradicated.  It will also present work that 
was aimed to take advantage of the James M. Slater Proton Treatment and Research 
Center facility at Loma Linda University Medical Center by providing evidence for an 
alternative and potentially more efficacious approach to pancreatic cancer treatment. 
 
The Inhibitor of Apoptosis Survivin 
Survivin controls diverse cellular functions including surveillance checkpoints, 
suppression of cell death, the regulation of mitosis, and the adaptation to unfavorable 
environments 2-5.  Its suppression of cell death activities and the baculovirus IAP repeat 
(BIR) domain characterize it as a member of the inhibitor of apoptosis (IAP) family of 
proteins 6. However, its lack of a COOH-terminal RING finger domain and the caspase 
recruitment domain 7 make it structurally unique among the mammalian IAPs.  The 
overall multifaceted functionality of survivin is still being intensely scrutinized, though it 
appears that protein compartmentalization plays an important role.  Survivin has been 
shown to colocalize in the mitochondria where it abolishes tumor cell apoptosis and 
promotes tumorigenesis in immunocompromised animals 8.  It, therefore, may possess a 
role in apoptosis similar to the pro-apoptotic Bcl-2 family of proteins.  Survivin has also 
been found in the nucleus and cytosol where it has roles in mitosis regulation and 
6 
apoptosis inhibition, respectively 9.  Survivin has been observed to be expressed in most 
common human cancers and, while present during embryonic and fetal development, 
survivin is undetectable in a variety of adult tissues 10.  Its aberrant, high protein 
expression in cancer cells and concomitantly low expression in most normal tissues 
makes survivin an important anticancer target 11.   
The accumulated data from the characterization of survivin expression in human 
cancer tissues reveals an overwhelming consistent observation that the expression of 
survivin is enhanced in various human cancers in comparison with the adjacent normal 
tissue.  Multiple therapeutic strategies have been successfully investigated including the 
molecular antagonists such as antisense oligos, RNA inhibition, dominant negative 
mutants, survivin-specific cytolytic T cells, a nonphosphorylatable survivin mutant 
Thr34Ala (T34A), and, most recently, binding interface mimetics 12-19.  The observation 
that a pool of survivin is localized extracellularly and is linked to erosive joint disease in 
a significant fraction of rheumatoid arthritis patients, and that an autoimmune response 
(survivin-targeting antibodies) to survivin correlates with protection from joint disease 
20,21 provides evidence that anti-survivin therapy may be possible in other pathologies 
such as cancer.  Work in our laboratory is currently defining the role of exosomal 
survivin in regulation of the tumor microenvironment 22. 
While many different therapeutic approaches have been employed, few have been 
aimed at regulation of survivin transcription.  This is owed in large part to the complexity 
of mechanisms involved in epigenetic, transcriptional, and post-transcriptional gene 
regulation.  It will likely require uncovering of all or most aspects of the machinery 
7 
involved in aberrant gene regulation to reach the goal of developing personalized medical 
approaches to treating unique cancer types. 
 
 
Survivin Transcription 
Survivin transcription is critical in embryogenesis, but is normally turned off in 
adult life 23.  However, survivin can be transcriptionally upregulated in adult life and 
often results in disease, particularly cancer.  Survivin is the fourth-most frequently 
overexpressed transcript in most human cancers 24, and the specificity of the survivin 
promoter for regulation in cancerous tissue has been demonstrated numerous times.  It is 
currently being investigated as a means of driving expression of therapeutic genes 25-27 
because its high degree of specificity to malignant cells which could decrease off target 
expression  of  a  suicide  gene  or  other  forms  of  gene  therapy.    Survivin’s  robust  and  
specific upregulation in cancer implies that the transcription factors involved in survivin 
transcription must be present and themselves upregulated in cancerous tissue.  Table 1 
summarizes the role of several key transcription factors in survivin transcriptional 
regulation. 
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Table 1: Summary of Key Transcriptional Regulators of 
Survivin (modified from Zhang et al., 2006. 
Pathway Key info and current status 
NF-KB Regulates survivin, but 
mechanism unclear 
p53 Transcriptionally 
downregulates survivin 
APC/Beta catenin/TCF-4 APC dowregulates survivin 
by inhibiting B-
catenin/TCF-4 
HIF-1D Transcriptionally 
upregulates survivin 
Sp1-DNA Interference of Sp1 
interaction-survivin 
interaction downregulates 
survivin 
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Activators of Survivin Transcription 
Survivin transcription is induced in part by the presence of cellular stress such as 
that induced by chemotherapeutic agents, radiotherapy, and aspects of the tumor 
microenvironment.  One such aspect of the tumor microenvironment that is common to 
most solid tumors is hypoxia and subsequent induction of neovascularization via VEGF 
and HIF-1D activation.  This has lead to investigation a possible relationship between the 
hypoxia-responsive gene HIF-1D and survivin.  A study from Wei et al. 28 found a strong 
correlation between HIF-1D and survivin expression in immunohistochemically analyzed 
pancreatic cancer samples.  Follow up studies found that use of antisense HIF-1D in 
pancreatic cancer BxPc-3 cells inhibited survivin expression and induced apoptosis in 
cells 29.  Peng et al. found an association between Epidermal Growth Factor (EGF) 
overexpression and survivin overexpression 30.  This EGF-related upregulation was 
mediated by HIF-1D transcriptional activation of the survivin gene, even under normoxic 
conditions.  Bai et al. more recently identified a strong relationship between survivin 
overexpression and HIF-1D overexpression in cervical cancer 31.  They show HIF-1D-
responsive element independent upregulation of survivin reporter constructs, specifically 
in the first 158 bp of the survivin promoter.  Indeed HIF-1D-mediated upregulation of 
survivin has now been observed in many cancer types including pancreatic, prostate 32, 
cervical 31, non-small cell lung 33, laryngeal 34, and colorectal cancer 35.  Efforts are 
underway to evaluate the effectiveness of disruption of HIF-1D expression as a means to 
sensitize cells to therapeutic modalities. 
It is now known that basal survivin transcription requires Sp1 (more will be said 
about Sp1 later in this dissertation) or KLF5 36,37, but there are numerous other 
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transcription factors and coactivators that are thought to drive high levels of survivin 
transcription.  NF-κB is one of these transcription factors.  It is a complex of proteins that 
are involved in inflammation, increased cell proliferation, metastasis, and inhibition of 
apoptosis.  One of the mechanisms by which it contributes to these phenotypes is by 
transcriptional activation of survivin 38-40.  Members of the signal transducers and 
activators of transcription (STAT) family are also transcription factors capable of binding 
and activating the survivin promoter 41.   
 
Downregulation of Survivin Transcription 
Several key proteins are also able to downregulate survivin transcription.  In 
addition  to  p53’s  critical  involvement  in  cell  cycle  checkpoint  regulation,  it  also  prevents  
the transcription of oncogenes such as survivin.  Retinoblastoma (Rb) and E2F have 
similar effects on survivin transcription 42.  However, these genes are often silenced, 
mutated, and/or nonfunctional in patients with cancer.  Therefore identification of other 
transcription factors that may negatively regulate survivin is of importance to cancer 
therapy.  Egr-1, a transcription factor that shares many similarities with YY1, has 
previously been noted to be involved in cell cycle, death, and differentiation.  Much like 
YY1, Egr-1 can either act as an activator or repressor depending on the promoter in 
question and the available coregulators with which it can interact.  Egr-1 has a consensus 
binding site that shares some overlap with the Sp1 transcription factor 43,44.  Interestingly, 
YY1 can also be repressive or activating depending on a number of factors, and it also 
shares some overlap with Sp1 binding sites for some of its targets 45.  This dissertation 
will show that the transcription factor YY1 may be involved in direct transcriptional 
repression of survivin, which may reveal a novel means of studying inhibition of survivin 
11 
transcription for therapeutic treatments. 
Natural agents are gaining increasing interest as a means of distrupting oncogene 
transcription, including survivin.  YM155, a small molecule inhibitor of survivin, has 
recently been investigated in Phase II clinical trials for a variety of cancers including 
diffuse large B-cell lymphoma 46, prostate cancer 47, melanoma 48, and non-small cell 
lung cancer 49 due to its previously observed ability to induce apoptosis and reduce tumor 
bulk in various in vitro and in vivo models 50.  This induction of cell death is thought to 
be due, at least in part, to its ability to decrease survivin transcription, but the mechanism 
by which it does this is still under investigation.  Nakamura et al. 51 recently found a role 
for interleukin enhancer-binding factor 3 (ILF3/NF110) in this observed inhibition of 
survivin expression by YM155.  They also found that in luciferase reporter experiments,  
ILF3-dependent upregulation of reporter activity could be attenuated with YM155, 
suggesting that ILF3/NF110 is a physiological target of YM155.  Currently, clinical trials 
are showing promise for YM155, particularly as a combination therapy to sensitize 
tumors to existing therapies.  Other natural agents are also showing potential for 
disruption of survivin transcriptional activity.  Specificity proteins Sp1, Sp3, and Sp4 
have long been known to be important transcription factors involved in the 
overexpression of survivin in human cancer.  However, little progress has been made to 
exploit this relationship for gains in therapeutic approaches to cancer.  Recently, 
curcumin was identified as a natural agent that inhibits the ability of Sp1, Sp3, and Sp4 to 
activate survivin transcription 52. It appears to do so by generating reactive oxygen 
species that upregulate repressors of Sp proteins ZBTB10 and ZBTB4, and 
downregulation of the microRNAs mir-20a, mir-27a, and mir-17-5p, that are regulators 
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of these Sp repressors.  Interestingly, curcumin is also showing promise as a sensitizing 
agent to ionizing radiation in Burkitt lymphoma and non-Hodgkin lymphoma 53,54. The 
natural agents Resveratrol and Quercetin in combination (RQ) have also shown a similar 
downregulation of Sp proteins and their targets, including survivin 55.  Interestingly, the 
authors  cite  RQ’s  antioxidant  capabilities  (as  opposed  to  curcumin’s  generation  of  
reactive oxygen species) as the potential reason for this observed repression of Sp protein 
and their transcriptional targets such as survivin.  These data further support the need for 
continued efforts to develop therapeutic approaches to cancer that include disruption of 
survivin transcriptional activation. 
 
The Multifunctional Transcriptional Factor Yin Yang-1 
Yin Yang-1 (YY1) is a 65-kDa ubiquitous multifunction transcription factor that 
is a member of the GLI-Kruppel family of nuclear proteins 56-58.  This family of proteins 
plays roles in development and exerts much of its function through cell cycle regulation.   
YY1 is a relatively unique transcription factor in that it can act by repressing some genes 
and activate others by binding to the specific DNA  sequence  5’-CGCCATNTT-3’  57,59.  
This phenomenon was noted first when it was shown that YY1, in the presence of the 
adenovirus-derived protein called E1A, represses the AAV P5 promoter 60.  When E1A is 
not present, YY1 then activates transcription 61. 
Reports suggest that YY1 is required for cell survival, as complete ablation of 
YY1 results in lethality 62.  Furthermore, array data suggests that YY1 has roles in cell 
cycle, cell adhesion, and other markers of disease aggressiveness 63,64.  As is true for 
survivin, YY1 is increasingly found to be involved in cell death regulation via NF-κB.  
Within the serum amyloid A gene, there is a binding site for NF-κB that was found to 
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overlap with a YY1 binding motif.  Lu et al. showed that YY1 binding was able to 
abrogate NF-κB binding and transcriptional activity.  A similar binding site overlap was 
observed in a cytomegalovirus promoter 65.  This offers some indirect evidence of YY1 
involvement in cell death, but more direct evidence is also emerging.  Evidence suggests 
that YY1 transcriptionally represses Fas, which in turn means that YY1 is a significant 
factor in resistance to Fas-induced apoptosis 66.  YY1 also appears to have a direct role in 
resistance to tumor necrosis factor-related apoptosis inducing ligand (TRAIL).  Recent 
findings show a direct role for YY1 negatively regulating transcription of death receptor 
5 (DR5), meaning YY1 is also a resistance factor for TRAIL-induced apoptosis 67. 
 
YY1’s  Role  in  Human Cancer 
 YY1 is gaining increasing interest as a cancer-related transcription factor.  
The oncogenic role of YY1 has been reviewed numerous times 68-70, yet many questions 
remain.  Consistent with its variable role as a transcription factor depending on a 
multitude of cellular and molecular conditions, it appears to have a variable role in cancer 
depending  on  what  type  of  cancer  is  being  studied.    Intriguingly,  YY1’s  role in some 
cancers appears to promote longer patient survival, whereas in others it correlates with 
poorer outcomes and shorter survival.  Table 2 summarizes current findings regarding 
YY1’s  role  in  various  cancer  types.    A  computational  analysis  of  YY1  expression in 
numerous data sets that looked at a broad array of cancer types indicates a relative 
increase in YY1 expression compared to expression in normal tissue.  Seligson et al. have 
shown that YY1 protein levels are higher in metastatic prostate cancer tissue than in 
primary tumor.  However, they also found a correlation with lower YY1 protein levels 
and survival, suggesting that lower YY1 levels may lend a survival advantage to 
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metastatic cells 71.  Further supporting a role for YY1 in prostate cancer formation, Deng 
et al. found that in prostate cancer YY1 interacts with androgen receptor (AR) to promote 
PSA transcription 72.   
 A similar association of YY1 with disease progression has been noted in 
intraepithelial neoplasms and cervical cancer.  YY1 expression in high-grade squamous 
intraepithelial lesions is higher than in low-grade squamous intraepithelial lesions, a 
finding also consistent with the observation that high expression correlates with the 
presence of Human Papilloma Virus infection 73. 
There are also many reports of a direct role for YY1 in aberrant cell cycle in 
cancer.  Numerous studies show that YY1 is involved in tumorigenesis via interactions 
with the tumor suppressor p53.  The general mechanism it appears to do this by is 
interference of p53-dependent transcription of its target genes by competing for binding 
to the ACAT sequence of promoters 74.  Also, YY1 has been shown to be essential for 
optimal interaction of MDM-2 and p53, which is required for MDM-2 ubiquitination of 
p53 75.  The importance of this finding cannot be overstated, as an estimated 50% of all 
tumors have p53-inactivating mutations 76. 
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Table  2:     YY1  expression   in  human  cancers   and   it’s   clinical   relevance   (modified   from  
Castellano et al. 68). 
Tumor Type Methods Clinical relevance of YY1 Overexpression Reference 
Prostate cancer IHC 
Positive correlation 
with metastasis and 
inverse relationship 
with poor outcome 
71 
Ovarian cancer Microarray Positive correlation with long-term survival 
77 
Ovarian c`ancer 
Microarray, 
IHC, RT-
PCR 
Positive correlation 
with survival and 
response to taxanes 
78 
Cervical 
neoplasms RT-PCR 
Positive correlation 
with disease 
progression 
73 
Osteosarcoma RT-PCR, IHC, WB 
Positive correlation 
with more malignant 
phenotype 
79 
Myeloid 
Leukemia RT-PCR 
Positive correlation 
with t(8;21) 
80 
Non-Hodgkin 
Lymphoma RT-PCR 
Positive correlation 
with poor outcome 
81 
Follicular 
Lymphoma IHC 
Positive correlation 
with length of survival 
82 
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Pancreatic Cancer: Toward Improved Combination Therapy 
Pancreatic cancer is the fourth leading cause of cancer-related death (refer to 
Figure 2).  Early detection of localized disease with subsequent surgical resection offers 
virtually the only hope of long-term survival to pancreatic cancer patients.   
Unfortunately, this represents only an estimated 10-20% of all patients.  Because 
chemotherapy has offered very minimal improvements in survival time, efforts to use 
radiation in combination have been explored and been met with some success 83.  Doses 
for radiation therapy are limited, however, by the proximity of other structures that are 
subject to bystander toxicity such as the liver, kidneys, stomach, spinal cord, and small 
intestines.  Proton radiotherapy is a powerful means of treating cancer as it offers the 
advantage of allowing delivery of a given radiation dose at the depth of a tumor, but not 
beyond.  Thus, non-tumor tissue beyond the tumor is spared from radiation and the long-
term complications of such exposure.  If off-target damage can be reduced, the dose of 
radiation used on the tumor can be increased to improve efficacy of the treatment.  
Unfortunately, tumors can develop radioresistance due to changes in molecular 
determinants of cell death.  
Reports suggest that survivin is one factor involved in imparting radioresistance 
to tumors.  In a study of pancreatic duct cell carcinoma (PDC) vs. precancerous 
intraductal papillary-mucinous tumor (IPMT), Satoh et al. found high survivin expression 
in PDC as opposed to very low expression in IPMT, suggesting that survivin is involved 
in the progression to a malignant phenotype in pancreatic cancer 84.   A second facet of 
this dissertation is exploration of combined therapy with gemcitabine and proton therapy.  
Currently, proton therapy is used mostly for prostate, brain, and head and neck cancer. 
This is largely due to ease of targeting these structures.  However, efforts are underway to 
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evaluate the effectiveness of proton therapy for pancreatic cancer.  A Phase II clinical 
trial at Loma Linda University Medical Center is currently exploring the role of proton 
therapy in combination with different chemotherapy regimens in locally advanced 
pancreatic cancer treatment.  In addition to advancing the understanding of potential 
advantages of proton therapy in pancreatic cancer cell death, the work presented in 
Chapter 3 presents evidence that survivin and its IAP family member X-linked IAP 
(XIAP) may be key molecular determinants of apoptosis and radioresistance in pancreatic 
cancer.  If a viable means of modulating survivin and XIAP levels in a clinical setting is 
discovered, this may offer a means of drastically improving response to therapy.   
 
Design of Studies 
The studies presented in the chapters to follow were designed to advance the 
understanding of both basic science aspects of cancer biology and provide data to 
improve the therapeutic approach to pancreatic cancer.  Most effective cancer therapies 
are based on a sound rationale that was developed from basic science research to discover 
molecular and cellular behavior after manipulations, whether they are genetic, medicinal, 
or immunological.  Chapter 2 of this dissertation details a study of transcriptional 
regulation of survivin in attempt to better understand factors involved in survivin 
overexpression in cancer.   To do this we used a luciferase reporter system that allows 
one to study promoter activity in the presence of modifying factors including cellular 
stress and transcription factor overexpression.  Furthermore, we used electrophoretic 
mobility shift assays (EMSA) to determine whether or not YY1 was capable of binding 
directly to the survivin promoter.  This is an important step to try to establish how a 
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transcription factor is affecting target gene expression because it can do so by many 
means aside from direct promoter binding.   
In Chapter 3, the goal was to discover if different doses and timing of a 
combination of gemcitabine and proton therapy could sensitize pancreatic cancer cell to 
enhanced cell death, and to see if this enhanced cell death correlated with survivin 
expression.  To study cell death after each treatment combination, we used propidium 
iodide flow cytometry and western blots to investigate the concomitant survivin 
expression.  We also chose to compare a radiosensitive cell line (MiaPaCa-2) with a 
radioresistant cell line (Panc-1) to better define the usefulness of proton therapy in our 
treatment schemes.   
These studies, done in cell culture models, were designed to establish preclinical 
rationales for later work to be done in animal models, or in the case of Chapter 3, 
patients.  As previously mentioned, efforts to develop therapeutic approaches based on 
transcription factor modulation are already underway, and clinical trials using proton 
therapy for pancreatic cancer are underway as well, including a Phase II clinical trial at 
Loma Linda University Medical Center. 
 
Importance of Studies 
 The advent of molecular biology has given scientists powerful tools to understand 
the mechanisms and architecture involved in cell structure and function, and has helped 
reveal the true complexity of biological systems.  A key feature of this complexity is 
redundancy, a concept that has plagued therapeutic approaches to cancer.  Molecular 
biology has revealed that virtually no cellular processes are without pathway redundancy, 
and cancer cells have perhaps even more redundancy than normal cells to better equip 
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them to evade immune response and death.  Gene expression, such as that of survivin, is 
affected by redundant epigenetic, transcriptional, and post-transcriptional regulation 
factors.  In order to most effectively exploit therapy directed against a target such as 
survivin, it is important to understand the complete picture of how the survivin gene 
works.  This dissertation will detail what we believe is a novel regulator of survivin 
transcription, YY1.  Specifically, YY1 may be a negative regulator of survivin and may 
be the focus of therapeutic approaches to cancer therapy in the near future. 
 In addition to obtaining a more complete understanding of molecular mechanims 
involved in oncogenesis and tumor suppression, it is critical to continue to design new 
therapeutic approaches based on sound reasoning arrived at through basic science 
research.  This dissertation also details the use of combined chemotherapy and proton 
radiation therapy as a means to treating pancreatic cancer.  Since our work began, clinical 
trials utilizing combined gemcitabine and proton therapy have been conducted in Japan, 
and are showing great promise 85.  One of the key limiting factors in radiation treatment 
is organ-related or systemic toxicity.  Proton therapy is an extremely effective means of 
delivery radiation while simultaneously sparing surrounding non-malignant tissue 
compared to standard gamma or x-ray radiation 86,87.  Currently, proton therapy is not 
used as a means of treating pancreatic cancer at Loma Linda Medical Center, but the 
work presented in Chapter 3 provides evidence that may stimulate more thought as to 
whether or not that should change. 
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Abstract 
Survivin is a member of the Inhibitor of Apoptosis (IAP) family of proteins, and 
is highly expressed in all cancers but absent in most non-proliferative normal tissue.  
Expression level correlates with chemo- and radioresistance, as well as poor prognosis in 
cancer patients.  The mechanisms for upregulation of survivin in cells undergoing stress 
associated with tumor development and the tumor microenvironment are not well 
understood.  The putative stress response transcription factors HIF-1D and Yin Yang 1 
(YY1) were hypothesized to contribute to the upregulation of Survivin in tumor cells.  
Examination  of  the  5’  flanking  region  of  human  survivin gene revealed the presence of 
multiple putative stress activated transcription factor binding domains that have 
previously been shown to be associated with HIF-1D and YY1.  In order to study basal 
regulation with luciferase reporter assays, U2OS cells were transfected with a variety of 
constructs of the survivin promoter.  As expected, cells overexpressing HIF-1D showed a 
2-3 fold transactivation of all promoter constructs tested.  Surprisingly, when YY1 is 
overexpressed in this survivin promoter reporter system, luciferase expression was 
repressed 30-40 fold.  YY1 involvement in survivin promoter repression was confirmed 
using siRNA directed against YY1.  These studies showed that knockdown of YY1 
releases the survivin promoter from the observed repression and leads to a 3-5 fold 
increase in promoter activity above basal levels.  A U2OS cell line containing a stable 
YY1 Tet-off system was used to determine whether a temporal increase in YY1 
expression affects Survivin protein levels.  A low to moderate decrease in Survivin 
protein was observed 24 hrs and 48 hrs after Tet removal. Studies also confirmed that 
YY1 is capable of directly binding to the survivin promoter.  Collectively, these findings 
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identify novel basal transcriptional requirements of survivin gene expression.  While 
HIF-1D may be in part responsible for the increased expression of survivin in tumor 
tissue, YY1 may also be induced under stressful conditions to negatively regulate 
survivin, suggesting that it is the balance of these transcription factors, and likely others, 
that may play an important role in the development of cancer and resistance to its 
treatment. 
 
Introduction 
Survivin, a unique mammalian inhibitor of apoptosis (IAP) protein, controls stress 
from the microenvironment through diverse functions within the cell including 
surveillance checkpoints, suppression of cell death, regulation of mitosis, and adaptation 
to unfavorable environments 2-4.  Unlike all other IAP family members, survivin is unique 
in that it has important regulatory roles in both apoptosis suppression and cell cycle 
progression regulation 88.  Survivin has been observed expressed in most common human 
cancers and present during embryonic and fetal development 10.  Its aberrant, high protein 
expression in cancer cells and concomitantly low expression in most normal tissues 
makes survivin an important anticancer target 11.  Strategies have been successfully 
investigated against survivin, including molecular antagonists such as antisense oligos, 
RNA inhibition, ribozymes, dominant negative mutants, survivin-specific cytolytic T 
cells, a nonphosphorylatable survivin mutant Thr34Ala (T34A), triplex DNA formation 
and most recently, binding interface mimetics 12-19,89-92. 
Epigenetic, genetic and post-translational mechanisms for survivin gene 
regulation have been described in many malignant cell types 42 with various transcription 
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factors including Stat3 41, HIF-1α  30, Rb-E2F1 93, Dec1 94, Sp1 36, c-myc 95 and KLF5 37 
affecting its transcriptional upregulation.  In addition, the tumor suppressor p53 and Rb-
E2F2 have been shown to repress survivin transcription by direct binding to the survivin 
promoter in a lung adenocarcinoma cell line 96 and in normal human melanocytes 42.  
Survivin’s promoter has been recorded to be differentially methylated in ovarian cancers 
as compared to normal ovarian tissues.  An interesting polymorphism has also been 
described at a CDE/CHR repressor element in the survivin promoter that correlates with 
increased survivin mRNA and protein in cancer cell lines and not in normal cell line 
controls 97. 
The transcription factor YY1 is known to have a fundamental role in normal 
biologic processes such as embryogenesis, differentiation, replication, and cellular 
proliferation 61.  YY1 exerts its effects on genes involved in these processes via its ability 
to initiate, activate, or repress transcription depending upon the context or recruited 
cofactors in which it binds 98,99.  One such family of cofactors are the histone 
deacetylases which have been shown to bind YY1 and repress transcription when 
targeted to promoters 100.  YY1 has been shown to interact with p300, PCAF and CBP, all 
which posses the histone acetyltransferase (HAT) activity 100.  YY1 may thus activate 
transcription by its recruitment of HAT proteins and repress trancription by recruiting 
HDACs. 
Poor oxygenation (hypoxia), owing to an inadequate blood supply, is a common 
feature of most solid human tumors and is associated with increased malignancy, 
resistance to therapy and distant metastasis 101.  Hypoxia inducible factor-1α  (HIF-1α),  a  
member of basic helix-loop-helix-PAS protein family 102,103, is usually increased under 
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hypoxic conditions, and can activate transcription of many genes that are critical for 
cellular function under hypoxic conditions 102. Previous studies have found that down-
regulation of HIF-1α  could  significantly  decrease  the  levels  of  survivin  expression  in  
BxPc-3 pancreatic cancer cells 29 and breast cancer cells 30.  HIF-1α  was  also  
demonstrated to directly bind to the survivin promoter, which strongly suggests that 
survivin gene expression is indeed mediated by HIF-1α  under  normoxic  conditions  30. 
In the present study, we examined the transcriptional affect of YY1 and HIF-
1Don survivin in an osteosarcoma cell line derived from human bone osteosarcoma 
(U2OS). We found that when YY1 and HIF-1D were overexpressed in U2OS cells, 
survivin mRNA and protein were repressed by YY1 and induced by HIF-1D.  By 
analyzing the survivin promoter activity, we further found that YY1 was a transcriptional 
repressor of the survivin gene while HIF-1α  was a transcriptional activator.  We also 
show, for the first time, that YY1 is capable of binding directly to the survivin core 
promoter and thus is acting as a transcription factor rather than an corepressor.   
 
Results 
Identification of Survivin Promoter Sites Involved in Transcriptional 
Regulation by HIF-1D and YY1 
  HIF-1D has previously been shown to be a transcriptional regulator of survivin 28,30,31. 
To determine possible bindings sites for YY1, using a computer-based approach the 
survivin promoter was scanned for putative HIF-1D and YY1 binding sites using the 
online tool TFSearch (www.cbrc.jp/research/db/TFSEARCH.html) and previously 
published consensus sequences 104.  Figure 1 shows the locations of all identified HIF-1D 
and YY1 consensus sites in the first 6280 bp of the survivin promoter.  Using Survivin 
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promoter nested deletions in a luciferase reporter system (previously described by Li and 
Altieri 105), the ability of YY1 and HIF-1 to activate or repress survivin promoter activity 
was tested (Fig 2. A).  The survivin promoter nested deletions were utilized to assist in 
identification of regions of the promoter that are essential to regulation of the survivin 
promoter by each transcription factor tested.  Therefore constructs ranging from 230 bp 
upstream of the surviving start site up to 6280 bp upstream of the start site were utilized. 
When HIF-1D was overexpressed in U2OS cells, an induction of 2-3 fold was seen in all 
constructs tested except +230 bp and +6280 bp.  However, when YY1 was 
overexpressed, contrary to our initial hypothesis, there was a 30-40 fold repression of 
survivin promoter activity in all constructs tested.  To further examine these findings, we 
evaluated endogenous survivin transcript levels after overexpression of HIF-1D and YY1 
in U2OS cells (Fig. 2B).  The results were consistent with survivin transcriptional 
upregulation by HIF-1D as seen in the previous reporter experiments, and downregulation 
of survivin after YY1 overexpression.   
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Figure 1.   Proximal survivin promoter schematic.  Using previously published putative 
DNA binding sites for YY1, HIF-1, and TFSearch, the survivin promoter was scanned for 
the presence of each of these putative binding sites.  Analysis revealed the presence of 
multiple putative YY1 binding sites, noted by bolded segments.  Similarly, analysis of the 
survivin promoter revealed several putative HIF-1 binding sites (noted as the boxed 
segments).  For reference, putative SP1 sites are also denoted as underlined segments. 
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Figure 2.  Effect of HIF-1 and YY1 overexpression on survivin  promoter activity and 
transcript levels.  (A) Luciferase reporter assays were performed using survivin promoter 
constructs in the pGL3Basic vector ranging in length from +6280 bp to +230 bp.  U2OS 
cells were transiently cotransfected with survivin construct DNA of the indicated length, 
and either YY1, HIF-1, or their respective empty vector for baseline promoter activity.  
Controls indicate relative values of expression when empty pGL3 was contranfected with 
empty transcription factor expression vector (Control 1) or empty pGL3 contransfection 
with the indicated transcription factor (Control 2).  Error bars represent the standard 
deviation of duplicate luminescence measurement.  Results are representative of repeat 
experiments.  (B) RT-PCR analysis of survivin expression following overexpression of 
YY1 and HIF-1. A (-) indicates that cells were transfected with the corresponding empty 
vector for each transcription factor. Beta actin is shown for reference as a loading control. 
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siRNA-mediated Knockdown of YY1 
Due to the unexpected and robust findings for YY1, it was chosen for further 
studies.  To provide further evidence for the ability of YY1 to affect basal survivin 
promoter activity, YY1 knockdown was performed (Fig. 3 A and B).  Because previous 
experiments showed survivin promoter activity repression across all constructs tested, 
pLuc1430, 393, and 281 were chosen for this experiment.  In U2OS (Fig. 3A) and Panc-1 
(Fig. 3B) cells alike, siRNA knockdown of YY1 relieved the survivin promoter of basal 
promoter activity repression, indicated by an increased in luciferase reporter activity of 
approximately 3-4 fold in each construct tested.  The overexpression of YY1 again 
repressed promoter activity to nearly undetectable levels, a finding consistent with 
previously described experiments.   
  
 
30 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  YY1 siRNA relieves the survivin promoter from transcriptional repression.  
Luciferase reporter assays were performed after YY1 overexpression and siRNA 
knockdown in (A) U2OS and (B) Panc-1 cells.  Three survivin promoter reporter 
constructs were tested (pluc1430, pLuc 393, and pLuc 281).  Relative expression 
indicates promoter activity relative to luciferase activity in the presence of empty pGL3 
vector and background pRL-tk activity.  Error bars represent the standard deviation of 
duplicate luminence measurements.  Results are representative of repeated experiments.   
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Protein Expression of Survivin is Modulated by YY1 Overexpression 
To investigate whether YY1 expression can affect survivin expression at the 
protein level, Western blot analysis was done using a U2OS YY1 tet-off cell line 
(previously described by Sui et al. 75).  Twenty-four hours after tet removal, a significant 
YY1 overexpression was seen (Figure 4).  Survivin protein levels remained unchanged at 
24 hours.  However, after 48 hours of incubation in tet-free media, a modest reduction in 
Survivin protein expression was seen. 
 
Site-directed Mutagenesis of Putative YY1 Bindings Sites in the 
Survivin Promoter 
Repression of survivin promoter activity in our luciferase reporter system was 
seen in all constructs tested, including the shortest construct containing 230 bp of the 
promoter, which has previously been shown to be the core promoter for survivin.  Fig. 1 
illustrates two putative YY1 binding sites within the first 230 bp of the survivin 
promoter, and we therefore wanted to investigate the involvement of these two sites as 
key areas involved in repression of basal survivin transcription by YY1.  Site-directed 
mutagenesis was employed to define the role of these two sites in survivin transcription.  
Fig. 5A illustrates the mutation of each CAT region of the putative YY1 sites to GGG.  
This region was chosen for mutation based on previous studies indicating that the core 
sequence preferred by YY1 is CCAT or ACAT 104.  When both putative YY1 binding 
sites were mutated, neither overexpression or knockdown of YY1 are able to alter the 
basal survivin promoter activity (Fig. 5B).  Furthermore, the basal survivin promoter 
activity (pcDNA empty vector only) was increased relative to non-mutated promoter 
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activity.  These data support a role for these putative YY1 binding sites in basal survivin 
transcriptional activity. 
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Figure 4.  Survivin expression decreases after 48 hours of YY1 overexpression.  Western 
blot analysis of survivin expression after YY1 overexpressionin via tet-off U2OS cells 
was analyzed.  A)  U2OS cells that stably express a YY1 overexpression vector under the 
control of a tetracycline responsive promoter were cultured to 70-80% confluency in the 
presence of 0.1 mg doxycycline.  They were then washed 7-8 times in tet-free media and 
cultured for either 24 or 48 hours in tet free media.  They were then lysed and protein was 
extracted for western blot analysis.  +/- indicates the presence or absence, respectively, of 
tet in the culture media.  (B)  Densitometric analysis of Western blot bands.  Bars 
represent density of YY1 (light bars) or survivin (dark bars) normalized to beta actin 
band density.  
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Figure 5.  Mutation of two putative YY1 binding sites in the proximal survivin promoter 
alters promoter activity  (A) The two most proximal putative YY1 binding sites 
(contained within pLuc230 construct)  were mutated from the core YY1 recognition site 
CAT to GGG.  (B) Luciferase reporter assay. U2OS cells were transfected with either (1) 
pLuc230, the standard pGL3 vector containing 230 unmutated bp of the survivin 
promoter, or (2) pLucMut in which the two putative YY1 binding sites were mutated 
from CAT to GGG.  Each vector was cotransfected with either empty pcDNA, YY1, or 
YY1 siRNA as well as pRL-tk for transfection efficiency internal control.  Error bars 
represent standard deviation of duplicate luminescence measurement, and results are 
representative of multiple experiments. 
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YY1’s  Interaction  with  the  Core  Survivin  Promoter 
YY1 can exert transcriptional changes via direct DNA binding or through protein-
protein interaction.  In order to determine if the survivin repression seen in reporter 
assays, RT-PCR, and Western blotting is through direct binding of YY1 to the survivin 
promoter at locations identified in Fig. 1, electrophoretic mobility shift assay was 
performed.  Two putative YY1 binding sites located in the survivin core promoter (Fig. 
6A) were studied.  To validate the study, a YY1 consensus sequence was used (Santa 
Cruz Biotechnology, Santa Cruz, CA).  Strong YY-1 binding to the consensus sequence 
was seen (lane 1, arrow).  Supershift (lane 2, asterisk) and cold competition (lane 3) 
confirmed the identity and specificity of the YY1 band.  When a probe for Site 1 was 
used, no binding or supershift was seen (lanes 4-5), indicating that it is not involved in 
YY1’s  regulation  of  survivin.    When  a  probe  for  Site  2  was  used,  a  double  band  was  seen  
at the appropriate location, possibly representing two different binding complexes 
involving YY1.  These bands were supershifted with the addition of YY1 antibody, and 
cold competition confirmed the specificity of the results.  Binding was enhanced by use 
of a probe containing both putative YY1 binding sites (lane 10).  Supershift and cold 
competitive again confirmed the specificity of the binding (lanes 11-12).   These results 
indicate that the most proximal putative YY1 binding site located on the survivin 
promoter is a target of YY1 binding and regulation, but binding to this site is increased 
with the inclusion of the second YY1 recognition site.     
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Figure 6: YY1 directly interacts with the survivin promoter.  (A) Schematic of survivin 
promoter representing regions investigated for YY1 binding.  (B) Electrophoretic 
mobility shift assay.  Nuclear extract was prepared from U2OS cells.  32p labelled probes 
(C) were incubated with nuclear extracts either alone (Lanes 1,4,7, 10), with anti-YY1 
antibody (lanes 2, 5, 8, 11) or cold competitor (CC) probes in 100x excess (lanes 3, 6, 9, 
12).  Arrow indicates YY1 bound to probe.  * indicates supershift.  (C) Probes used in 
EMSA, with underlined segments representing putative YY1 binding sites.  Result is 
representative of two experiments showing similar results. 
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Discussion 
 YY1 is increasingly recognized as a transcription factor that plays an important 
role in cancer, although there is a great deal of controversy as to whether YY1 promotes 
or inhibits cancer development and progression.  While many studies have focused on 
YY1 expression levels in tissue samples and the correlation of YY1 levels with clinical 
outcomes, metastasis free intervals, and response to therapy, far fewer studies have 
identified molecular mechanisms by which this multifunctional transcription factor is 
contributing to cancer pathology. We believe that this work shows, for the first time, a 
direct role for YY1 in survivin transcription, and that YY1 contributes to reduced basal 
expression levels of survivin.  However, in the current study the osteosarcoma cell line 
U2OS was utilized, and it is therefore unclear if this observed transcriptional repression 
of survivin by YY1 is generalizable to a broad array of cancer types.  Zhang et al. studied 
the role of YY1 on anti-apoptotic factors in colorectal carcinoma and found that siRNA-
mediated knockdown of YY1 in HCT116 and LOVO cell lines resulted in a decrease in 
survivin protein levels and increased levels of apoptosis 106.  This is also consistent with 
clinical findings of a correlation between high YY1 levels and increased disease 
aggressiveness in various cancer types.  Indeed de Nigris et al. found that in patients with 
osteosarcoma, YY1 overexpression correlated with increased metastasis and poor clinical 
outocome 107.  They also found that deletion of YY1 in the osteosarcoma cell line SaOS-2 
lead to decreased cellular invasion and metastasis, possibly related to VEGF and CXCR4 
regulation 108.  Other work has found that YY1 levels correlate with longer survival and 
decreased invasive potential.  In follicular lymphoma biopsy samples, higher expression 
levels of YY1 correlated with longer patient survivial 82. Wang et al. (2007) found that 
YY1 contributed to the increased expression of the tumor suppressor HLJ1 and related 
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decreased in in vitro cancer cell invasiveness.  The transcriptional and post-
transcriptional network regulation survivin expression is complex (reviewed by Zhang et 
al. 109),  and  it  is  therefore  possible  that  downstream  of  YY1’s  downregulation  of  survivin  
transcription other factors are significantly involved in determining the ultimate 
expression of survivin and the clinical sequelae that result.  It is also important to note 
that while our work demonstrates robust surivivin promoter activity reduction via 
reporter assay, the resulting reduction in mRNA and protein is more modest.  The extent 
to which YY1-mediated reduction of survivin expression results in increased apoptosis, 
alterations in cell cycle progression, or modulation of other hallmarks of cancer 
progression is currently under investigation in our laboratory.       
Work by Affar et al. 63 previously showed that in an mouse YY1 knockdown 
model, survivin (BIRC5) levels were decreased.  This lead us to initially hypothesize that 
YY1 overexpression in our hands would show a positive correlation with survivin 
expression.  We observed instead a robust negative correlation between YY1 
overexpression and survivin promoter activity that was also seen, although more 
modestly, at the protein level.  Interestingly, when the human survivin core promoter 
sequence is compared to the mouse survivin core promoter, of note is a lack of homology 
at both putative YY1 sites investigated in this study with site-directed mutagenesis (Fig. 
7).  This may, at least in part, explain why YY1 appears to negatively regulate survivin 
transcription in our cell culture model, whereas in mice it may positively regulation 
survivin expression. 
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Figure 7.  Comparison of human and mouse survivin promoter sequences.  Boxed 
segments represent the 2 putative YY1 binding segments of the survivin promoter 
contained within the pLuc230 construct that were mutated in previous experiments.  
There is lack of homology between mouse and human at both putative YY1 binding sites 
found in the first 230 bp of the survivin promoter.    HIF-1α  and  Sp1  bindings  sites  are  
shown for reference.   
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We provide several lines of evidence that YY1 represses survivin promoter 
activity in U2OS cells.  YY1 can regulate targets genes through a host of mechanisms 
including protein-protein interactions that allow it to act as a coactivator or corepressor 
and by direct DNA binding.  In the present study we identified a sequence of the survivin 
core promoter containing a putative YY1 binding and went on to show that YY1 is 
capable of binding directly to the most proximal of these putative binding sites.  Binding 
affinity for the survivin promoter was lower than for a consensus sequence known to 
efficiently bind YY1 110, and we believe that this likely represents a technical limitation 
owing to the extremely high GC content (70-80%) of the survivin promoter.  Because of 
the highly complicated nature of transcriptional regulatory networks, it is also possible 
that a proper scaffold is required for optimal binding.  Although YY1 binding occurs at 
the most proximal site on the survivin promoter (Site 2), binding is improved by 
inclusion of a second putative YY1 binding site (Site 1) that by itself does not appear to 
facilitate YY1 binding (see Fig. 6).      
There are many proposed models for how YY1 exerts its activating or repressing 
effects on promoters (reviewed by Gordon et al. 70), including displacement of 
transcriptional activators.  Sp1, a known activator of survivin transcription, is also known 
to physically interact with YY1 111,112.  Known Sp1 binding sites are located in close 
proximity to the YY1 binding sites examined in the current study, so it would therefore 
be valuable to design future studies to explore the role of Sp1 in YY1-mediates survivin 
repression.  Also, the known repressor of survivin transcription p53 96,113 is itself 
negatively regulated by YY1 75.  Therefore future studies should also examine the 
interplay of p53 and YY1 expression in survivin transcriptional regulation.   
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It was previously believed that targeting of transcription factors as means of 
cancer therapy was not practical owing to the complexity of transcriptional networks.  
However, it is increasingly believed that drug or small molecule inhibitor-mediated 
interruption of transcription factor binding represents an important approach to cancer 
therapeutics.  The small molecule inhibitor YM155 is currently in phase II clinical trials 
for several types of cancer including diffuse large B-cell lymphoma 46, prostate cancer 47, 
melanoma 48, and non-small cell lung cancer 49 due  to  it’s  previously  observed  ability  to  
induced apoptosis and reduce tumor bulk in various in vitro and in vivo models 50.  
Reduction in survivin transcription after YM155 treatment has been reported 114 and is 
believed to be a key mechanism for the apparent sensitization of tumors to cell death that 
has been observed. 
Our discovery of a novel transcriptional repressor of survivin may provide new 
ways of understanding survivin expression in the context of cellular stress resulting from 
chemo- and radiotherapy.  We also provide evidence for a possible positive role in YY1 
overexpression in human cancer.  The clinical significance of this finding across different 
cancer types has yet to be determined. 
 
Materials and Methods 
Antibodies and DNA Vectors 
All antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, 
USA) unless otherwise indicated.  The plasmid expressing YY1 protein, pcDNA3/YY1 
as well as the U6/yy1 siRNA and control U6/scrambled were kind gifts of Dr. Sui, Wake 
Forest and were described previously 75.  Survivin nested deletion constructs were 
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previously described 36 and were a kind gift from Dr. Li, Roswell Park Memorial 
Institute. 
 
Cell Culture and Transfection 
The U2OS human osteosarcoma cell line was obtained from ATCC.  U2OS cells with 
stable Tet-off YY1 were a kind gift from Dr. Sui, Wake Forest and were previously 
described 75.  Both cell lines were maintained under an atmosphere of 5% CO2 at 37°C in 
McCoys 5A media supplemented with 10% fetal bovine serum, 2 mmol/L of l-glutamine, 
and penicillin-streptomycin.  The Tet-off cells were additionally maintained in G418, 
hygromycin B, and the tetracycline analogue doxycycline (50 ng/mL).  YY1 expression 
was induced by transferring the cells to Tet-off medium, which is the same as control 
(Tet-on) medium except for the lack of doxycycline 75. 
 
Transient Transfection and Reporter Assays 
U2OS cells were seeded in 12-well plates and grown to 60 - 80% confluence.  A total 0.4 
ug of the various survivin promoter-luciferase reporter plasmids were cotransfected with 
either 0.6 µg of pcDNA/YY1 or empty vector expression plasmids and 0.01 ug of pRL-tk 
using FuGENE 6 (Roche, Indianapolis, IN). Approximately 24h after transfection, cells 
were lysed and assayed for luciferase activity by luminometer (Turner Design Systems, 
Sunnyvale, CA). Luciferase activity measurement was accomplished according to 
manufacturer’s  instructions, with the noted modifications.  Briefly, cells were washed in 
PBS, pH 7.4, solubilized in 1 x lysis buffer (Promega, Madison, WI) and scraped with a 
rubber policeman, then a 5 uL aliquot of the supernatant was mixed with 20 uL of Dual-
Glo® Luciferase Reagent (Promega, Madison, WI) and analysed on a Lumat 
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luminometer.  20 uL of Dual-Glo® Stop & Glo® Reagent was then added and a second 
reading on the Lumat luminometer was taken.  A ratio of luminescence of the first 
measurement (pGL3-survivin) to the second measurement (constitutively active pRL-tk) 
was calculated and reported for each vector and transcription factor combination tested.  
The pLuc230 vector containing CAToGGG mutation used for reporter experiments was 
purchased from Origene, Rockville, MD. 
 
Western Blots 
Cells were solubilized, proteins (20–40 Pg) separated using 12 % Bis-Tris 
polyacrylamide gels, transferred onto polyvinylidene difluoride membranes (Millipore) 
and probed using the following antibodies:  mouse monoclonal anti-YY1 (Santa Cruz 
Biotechnology, Inc., Santa Cruz, CA), and rabbit polyclonal anti-survivin (Novus, 
Littleton, CO).  Secondary antibodies (IR-Dye-conjugated) were goat anti-rabbit and goat 
anti-mouse immunoglobulin (LICOR, Lincoln, Nebraska).  Immunoreactive bands were 
detected using the Odyssey imaging system (LICOR) and quantified using ImageQuant 
software. 
 
Reverse Transcriptase-PCR 
Total RNA was extracted from cells at various time intervals using TRI-Reagent (Sigma, 
St. Louis, MO) and reverse-transcribed with SuperScript™  II  RNase  H- Reverse 
Transcriptase  (Invitrogen™,  Carlsbad, CA), as described by the manufacturer and 
amplified with survivin-specific primers. One hundred nanograms of the resulting first-
strand cDNA was used as template and amplified by PCR.  Sequences of the 
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oligonucleotide primer sets used for reverse transcription-PCR  analysis  are  as  follows:  5′-
GCA TGG CTG CCC CGA CGT TG -3′  (sense)  and  5′-GCT CCG GCC AGA GGC 
CTC AA -3′  (antisense)  for  survivin,  5′-GCT TCG AGG ATC AGA TTC TCA TCC -3′  
(sense)  and  5′- GAC TAC ATT GAA CAA ACG CTG GTC -3′  (antisense)  for  YY1,  5′- 
GCC AGA TCT CGG CGA AGT AAA -3′  (sense)  and  5′- ATA TCC AGG CTG TGT 
CGA CTG -3′  (antisense)  for  HIF1,  5′- ATG ACT CGC GAT TTC AAA CCT -3′  (sense)  
and  5′- CTT TGA AGT CGA GAA TCC ATT -3′  (antisense)  for  p75/LEDGF,  and,  5′-
CTCATGACCACAGTCCATGC-3′  (sense)  and  5′-TTACTCCTTGGAGGCCATGT-3′  
(antisense) for beta actin.  Products were visualized on ethidium bromide-stained agarose 
gels.  Amplification of beta actin served as an internal control. 
 
Electrophoretic Mobility Shift Assay 
Nuclear extracts were prepared as previously described 115, with the only modification 
that that N-N-(L-3- trans-carboxyoxirane-2-carbonyl)-L-leucyl-agmatine (E64) and 4-(2-
Aminoethyl)-benzolsulfonyl  ̄ourid  (`Pefabloc  SC')  were  included  as  protease  inhibitors  in  
concentrations suggested by the manufacturer (Boehringer, Mannheim, Germany). 
Protein concentration in nuclear extracts was determined using the BCA assay (Pierce) 
according to the manufacturers instructions.  Oligos used were as follows:  Two YY1 
sites  (YY1  sites  underlined):    5’- GC GCT CCC GAC ATG CCC CGC GGC GCG 
CCA TTA ACC GCC A -3’;;  YY1  Site  1    5’- TG CGC TCC CGA CAT GCC CCG CG -
3’;;  YY1  Site  2  CGC GGC GCG CCA TTA ACC GCC A -3’  YY1  Consensus  5’-CGC 
TCC CCG GCC ATC TTG GCG GCT GGT-3’.    All  oligos  were  annealed  by  incubating  
at 95% for 2 min, then cooling to room temperature slowly.  The DNA-protein binding 
reaction was performed in 20 ul reaction mixtures including 10% glycerol, 12 mM 
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HEPES ph 7.9, 4 mM TrisHCl ph 8.0, 1 mM EDTA, and 3 ug BSA.  Binding reactions 
were incubated at room temperature for 30 minutes, then for an addition 60 minutes at 4 
degrees C with anti-YY1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA sc-281) 
added to the appropriate reactions. The DNA-protein complexes were resolved on 5.5% 
non-denaturating polyacrylamidgel (29 : 1 cross-linking ratio), dried and exposed using 
the Storm 860 Phosphoimager (Amersham Biosciences). 
 
Statistical Analysis 
All data in reporter assay and semiquantitative PCR are presented as means r standard 
deviation.  
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Abstract 
OBJECTIVES:  This study evaluates the efficacy of combining proton irradiation 
with gemcitabine and the role the inhibitor of apoptosis proteins (IAP) survivin & XIAP 
play in the radiosensitive vs. radioresistant status of pancreatic cancer.  METHODS:  The 
radioresistant (PANC-1) and radiosensitive (MIA PaCa-2) pancreatic carcinoma cells 
response to combined gemcitabine and proton irradiation was compared.  Cells were 
treated with 0.1 - 500 PM gemcitabine and 0 - 15 Gy proton irradiation after which 
Trypan blue and flow cytometry were utilized to determine changes in the cell cycle and 
apoptosis.  Expression levels of survivin were measured using Western blotting.  
Combination therapy with 24 h gemcitabine followed by 10-Gy proton irradiation proved 
most effective.  RESULTS:  Gemcitabine and proton irradiation, resulted in increased 
survivin levels, with little apoptosis.  However, combination therapy resulted in robust 
apoptotic induction with a concomitant survivin & XIAP reduction in the MIA PaCa-2 
cells with little effect in the PANC-1 cells.  siRNA studies confirmed a role for XIAP in 
the radioresistance of PANC-1 cells.  CONCLUSIONS:  Our data demonstrate that 
combining gemcitabine and proton irradiation enhances apoptosis in human pancreatic 
cancer cells when XIAP levels decrease. Therefore, XIAP may play an important role in 
human pancreatic cancer proton radioresistance. 
 
Introduction 
Pancreatic cancer is the fourth most common cause of cancer death in men and 
women in the United States, with 5-year survival for all stages of disease less than 5% 116.  
Pancreatic cancer has no clear early warning signs or symptoms and is usually silent until 
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the disease is well advanced.  Patients have a median survival of 4-8 months after 
diagnosis due in part to the advanced stage the disease has already attained by the time it 
is discovered and treatment has begun.  Risk factors include age with diagnosis occurring 
in people ages 65-79, smoking, sex, and possibly diets high in fat 117.  Currently, if 
diagnosed early, surgical resection remains the only viable cure.  However, only 20% of 
pancreatic cancer patients meet these criteria 118.  It is therefore necessary to discover 
new therapies or therapeutic combinations in order to significantly impact this deadly 
disease.  The anti-metabolite agent gemcitabine is currently being employed to treat 
pancreatic cancer 119. While gemcitabine has shown significant benefit in clinical 
applications, its ability to more than modestly impact pancreatic cancer is limited.  It has 
been speculated that combinatory treatments using gemcitabine and other 
chemotherapeutics or radiotherapeutics could improve survival rates 120,121.  Proton 
radiotherapy has been investigated for a number of cancer types including cancers of the 
prostate, head & neck and brain 122-124.  Protocols are also currently in progress or 
development for treating a variety of additional cancer types including: carcinoma of the 
nasopharynx, paranasal sinus carcinoma, non-small-cell lung carcinoma, hepatocellular 
carcinoma and pancreatic cancer 125.  Pancreatic cancers though inherently resistant to 
photon radiation may be safely treated using protons.  Proton therapy allows dose 
escalation to improve local tumor control in anatomic sites and histologies where local 
control is suboptimal with photons 124.  This improved dose localization reduces normal-
tissue doses resulting in lower acute and late toxicity. 
Survivin, a member of the inhibitor of apoptosis protein (IAP) family has 
previously been shown to be a prognostic marker for pancreatic cancer patients 84,126,127 
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and has also been implicated in cancer cell radio- and chemotherapy resistance 88.  Many 
recent reports have demonstrated that inhibiting survivin expression by antisense 
oligonucleotides 128, dominant negative mutation 14,129, and ribozyme 130 can reduce 
cancer cell radio- and chemoresistance and may be important to resensitize these tumors 
to therapy. 
The goal of this study was to examine the combined affect of gemcitabine and 
proton irradiation on the pancreatic cell lines PANC-1 (photon radioresistant) and MIA 
PaCa-2 (photon radiosensitive) and to determine whether the same survivin involvement 
in proton radiation resistance would be observed129,131,132. 
 
Materials and Methods 
Cell Cultures 
Pancreatic carcinoma (Panc-1 & MIA Paca-2) cells were obtained from the 
American Type Culture Collection (ATCC) and maintained in DMEM supplemented 
with 100 units of penicillin, 100 Pg/ml streptomycin, 300 Pg of L-glutamine and 10% 
heat inactivated FBS (ATCC).  MIA PaCa-2 media also included 2.5% horse serum 
(ATCC). Cells were grown at 37 °C in a humidified atmosphere of 95% air, 5% CO2.  
Gemcitabine or Gemzar (Eli Lilly and Company, Indianapolis, Indiana) was dissolved 
in water and added to cells for the duration of 24 hours prior, simultaneously or 24 hours 
after radiation exposure.  Post treatment, the cells were returned to the incubator for an 
additional 24, 48, or 72 h.  All radiation procedures were accomplished in the Loma 
Linda University Radiobiology Proton Treatment Facility, now the James M. Slater, 
MD, Proton Treatment and Research Center.  Cells were exposed in vitro to 250 MeV 
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protons with doses ranging from 0 to 15 Gy at four different dose rates: a low dose rate 
of 2.5 Gy/h, an intermediate dose rate of 5 Gy/h and two high dose rates of 10 and 15 
Gy/h.  Cells are treated as shown in Figure 1. 
 
Apoptosis and Cell Cycle Analysis 
Subconfluent cultures of the various cell lines were incubated with vehicle 
(water), gemcitabine (0 to 500 PM) or exposed to proton irradiation (0 to 15 Gy/h) for 0, 
24, 48, and 72 hours at 37°C or combinations of gemcitabine and proton irradiation 
described above.  Cells were harvested, prepared, and analyzed for DNA content as 
described previously 133.  DNA content was analyzed using a Becton Dickinson FACScan 
flow cytometer (Becton Dickinson, San Jose, CA).  The distribution of cells in the 
different phases of the cell cycle was analyzed from DNA histograms using BD 
CellQuest software (Becton Dickinson and Company, San Jose, CA) and FlowJo software 
(Tree Star, Ashland, OR). 
 
Western Blot Analysis 
Cells were solubilized, proteins (20–40 Pg) separated using 12 or 15% Bis-Tris 
polyacrylamide gels, proteins transferred onto nitrocellulose membranes (Bio-Rad) and 
probed using the following antibodies: rabbit polyclonal anti-survivin (Novus, Littleton, 
CO) and GAPDH (Cell Signaling Technologies, Beverly, MA), and polyclonal E-actin 
(Abcam, Cambridge, MA).  Secondary antibodies (IR-Dye-conjugated) were goat anti-
rabbit immunoglobulin (LICOR, Lincoln, Nebraska).  Immunoreactive bands were 
detected using the Odyssey imaging system (LICOR) and quantified using ImageQuant 
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software.  Protein quantifications presented in this report were normalized with respect to 
GAPDH or E-actin as indicated. 
 
siRNA Knockdown   
siRNA oligos were obtained for Survivin and XIAP knockdown (Santa Cruz 
Biotechnology, Santa Cruz, CA).  In addition, a scramble siRNA was purchased for 
control.  Amaxa Nucleofection technology was employed for transfection of PANC-1 
cells.  PANC-1 cells were cultured as described above and passaged 3 days before 
transfection.  Nucleofection Kit R was used.  PANC-1 cells were trypsinized, counted, 
and aliquoted into 1x106 cells per tube.  Cells were spun down and resuspended in 100 uL 
of nucleofection solution.  To this 1.5 ug of siRNA was added, the suspension was 
transferred to a nucleofection cuvette, and the suggested program was applied..  
Immediately after program completion, 500 uL of fresh media was added and the cells 
were aliquoted equally into 6-well plates for further culture and treatment.  Cells were 
cultured for 3 days after transfection to allow for gene knockdown.  After this time, the 
appropriate treatments were applied. 
 
Statistical Analysis 
Statistical analysis was performed using a two-way analysis of variance 
(ANOVA) with the aid of JMP statistical software (Cary, NC).  A paired t test was used 
for group analysis. 
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Results 
Gemcitabine-Induced Survivin Protein is Associated with Growth 
Inhibition and Cytotoxicity in Pancreatic Cancer Cells 
Treatment of PANC-1 or MIA PaCa-2 cells with various concentrations (100 µM, 
10 µM and 1.0 µM) of gemcitabine resulted in a modest G0/G1 phase cell cycle arrest at 
24 h, followed by the progressive appearance of apoptosis over the 48-72 h time interval 
(Figure 2A).  Dose escalation of gemcitabine was insignificant, as 1 PM was as effective 
as 100 PM in inducing cell cycle arrest as well as apoptotic cell death in both cell lines.  
Between cell lines, the more radiosensitive MIA PaCa-2 cells were also more sensitive to 
gemcitabine than the radioresistant PANC-1 cells.  Both cell lines in their non-treated 
resting state exhibited between a 10 and 20%  
polyploid fraction (cells containing greater then 4N DNA).  Interestingly, after cells were 
gemcitabine treated, this polyploid fraction disappeared in both cell lines (Figure 2A). 
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Figure 1.  Treatment schematic. Gemcitabine and protons were given at time = 0.  
Combination treatment of gemcitabine followed by proton radiation was treated with 
gemcitabine given at -24 hrs and then followed by proton irradiation at time = 0  (Gem  →  
Proton).  Simultaneous treatment was accomplished with both modalities being given at 
time = 0 (Proton + Gem). Proton irradiation was administered 24 hrs before gemcitabine 
treatment  at  time  =  24  (Proton  →  Gem).    All  cells  were  harvested  24,  48,  and 72 hrs after 
its final treatment was administered. 
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Figure 2A.  Gemcitabine treatment of PANC-1 and MIA PaCa-2 cell lines.   Cells were 
treated using 0 PM,1 PM, 10 PM, and 100 PM gemcitabine after which they were 
harvested and analyzed for DNA content by propidium iodide staining and flow 
cytometry at 24 hr, 48 hr, and 72 hr. Percentages of apoptotic cells with hypodiploid 
(sub-G1) DNA content as well as those in G0/G1, S, G2/M and polyploid are indicated per 
each condition tested. Data are the mean r SD of three independent experiments 
(*p<0.01, **p<0.001).  
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Figure 2B. Detergent-solubilized extracts of pancreatic cells treated with gemcitabine 
were analyzed at the indicated time intervals for reactivity with antibodies for survivin 
and GAPDH (loading control), by Western blotting.  Molecular-weight (Mr) markers in 
kilodaltons are shown on the left. 
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Treatment of both PANC-1 and MIA PaCa-2 cell lines for 24 h with gemcitabine 
resulted in a dose-dependent reduction in survivin levels by Western blot analysis (Figure 
2B).  Further gemcitabine incubation of 48 h and 72 h resulted in survivin protein levels 
being enhanced or unchanged at doses of 1 and 10 PM in both cell lines, a result that is 
most likely due to drug-induced stress 134.  As a dose of 10 PM gemcitabine induced a 
time dependent G0/G1 arrest, enhanced cytotoxicity and 24 h reduction in survivin, this 
dose was chosen for all further experiments with MIA PaCa-2 cells.  However, PANC-1 
cells were treated with 100 PM gemcitabine due to their resistance to gemcitabine-
induced cell death. 
Treatment of PANC-1 or MIA PaCa-2 cells with various concentrations (0, 2.5, 5, 
10, and 15 Gy) of proton irradiation resulted in significant cell cycle arrest in both the 
radiosensitive MIA PaCa-2 as well as the radioresistant PANC-1 pancreatic cell lines in a 
dose-dependent manner (Figure 3A).  Unlike the results of gemcitabine in these two cell 
lines, only the radiation sensitive MIA PaCa-2 cells were induced to undergo notable 
levels of apoptosis.  MIA PaCa-2 cells experienced a time and dose-dependent apoptosis 
with the G2/M arrested cells being the most sensitive as it is from this population of cells 
that the highest level of time-dependent death is recorded.  Photon radioresistant PANC-1 
cells were also resistant to proton radiation (Figure 3A) even though these cells also 
experienced a dose-dependent cell cycle arrest.  In both cell lines, proton radiation 
induced a dose-dependent increase in polyploid cells from the 10% observed in the 
untreated controls to almost 30% in those treated with 15 Gy (Figure 3A). 
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Figure 3A.  Proton irradiation of PANC-1 and MIA PaCa-2 cell lines.  Cells were treated 
using 0, 5, 10 or 15 Gy of proton radiation after which they were harvested and analyzed 
for DNA content by propidium iodide staining and flow cytometry at 24 hr, 48 hr, and 72 
hr. Percentages of apoptotic cells with hypodiploid (sub-G1) DNA content as well as 
those in G0/G1, S, G2/M and polyploid are indicated per each condition tested. Data are 
the mean r SD of three independent experiments (*p<0.01, **p<0.001). 
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Figure 3B. Detergent-solubilized extracts of pancreatic cells treated with proton radiation 
were analyzed at the indicated time intervals for reactivity with antibodies for survivin 
and E-actin (loading control), by Western blotting.  Molecular-weight (Mr) markers in 
kilodaltons are shown on the left.  
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Treatment of both MIA PaCa-2 and PANC-1 cells lines with proton radiation 
resulted in a dose-dependent increase in survivin protein as defined by Western blot 
analysis (Figure 3B).  This increase in survivin protein concomitant with the observed 
G2/M arrest is expected as survivin has been previously shown to be expressed during 
cell division in a cell cycle-dependent manner 134. 
 
Sequential Treatment of Pancreatic Cancer Cells with Gemcitabine 
and Proton Irradiation Enhances the Effect of Single Agent Treatment 
in only MIA PaCa-2 Cells 
Treatment of MIA PaCa-2 cells with 10 PM gemcitabine (Figure 2A) and 10 Gy 
proton radiation (Figure 3A) resulted in modest levels of apoptosis, cell cycle arrest and 
survivin modulation in both cell lines with the most prominent killing effect in MIA 
PaCa-2 cells.  We therefore combined the two modalities as shown in Figure 1. 
Treatment of MIA PaCa-2 cells (Figure 4A) with 10 PM gemcitabine or 10 Gy 
proton irradiation resulted in cell cycle arrest at G0/G1 and G2/M respectively.  For 
sequential treatments that include gemcitabine as the first modality in the treatment 
regimen, G0/G1 arrest was also the prominent phenotypic cell cycle change and likewise a 
G2/M arrest resulted from sequential treatments that used proton irradiation as the first 
modality in the treatment regime.  Cell cycle arrest was followed by the progressive 
appearance of apoptosis over the 72 h time interval.  However, sequential treatments 
where gemcitabine lead proton irradiation resulted in an enhanced apoptosis by 48 h, a 
trend that increased further by 72 h.  An interesting observation first made with the single 
agent treatment experiments (Figure 2 & 3) is that gemcitabine treatment does not result 
in significant numbers of cells having greater than 4N DNA (polyploidy) while proton 
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irradiation results in a progressive accumulation of polyploid cells.  This is also observed 
in the sequential treatments where proton irradiation leads gemcitabine treatment.  
However, where gemcitabine and proton are given concurrently, little enhancement of 
this polyploid fraction is recorded and where gemcitabine leads the proton irradiation, an 
unremarkable number of polyploid cells are recorded (Figure 4A). 
Like MIA PaCa-2 cells, treatment of PANC-1 cells (Figure 4B) with 100 PM 
gemcitabine or 10 Gy proton irradiation alone or those combinations that lead with 
gemcitabine or proton irradiation also resulted in cell cycle arrest in G0/G1 and G2/M 
respectively.  However, unlike MIA PaCa-2 cells, sequential treatments did not result in 
the progressive appearance of apoptotic cells, even though 10 fold higher concentration 
of gemcitabine was used.  In fact, after 72 h of treatment, no significant changes are 
observed from those recorded after only 24 h of treatment.  Polyploidy does however, 
match what was observed in the MIA PaCa-2 cells (Figure 4A). 
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Figure 4A.  Combination Gemcitabine and Proton Radiation in PANC-1 and MIA PaCa-
2 cell lines. (A) PANC-1 and (B) MIA PaCa-2 cells were treated using 10 Gy of proton 
radiation and 10 PM gemcitabine after which they were harvested and analyzed for DNA 
content by propidium iodide staining and flow cytometry at 24 hr, 48 hr, and 72 hr.  
Percentages of apoptotic cells with hypodiploid (sub-G1) DNA content as well as those 
in G0/G1, S, G2/M and polyploid are indicated per each condition tested. Data are the 
mean r SD of three independent experiments (*p<0.01). 
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Figure 4B.  Combination Gemcitabine and Proton Radiation in PANC-1 and MIA PaCa-
2 cell lines. (A) PANC-1 and (B) MIA PaCa-2 cells were treated using 10 Gy of proton 
radiation and 10 PM gemcitabine after which they were harvested and analyzed for DNA 
content by propidium iodide staining and flow cytometry at 24 hr, 48 hr, and 72 hr.  
Percentages of apoptotic cells with hypodiploid (sub-G1) DNA content as well as those 
in G0/G1, S, G2/M and polyploid are indicated per each condition tested. Data are the 
mean r SD of three independent experiments (*p<0.01). 
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Modulation of Survivin Protein Expression by Combining 
Gemcitabine and Proton Irradiation in Pancreatic Cancer Cell Lines 
To determine the potential relevance of targeting survivin for tumor cell apoptosis 
in sequential gemcitabine and proton irradiation treatments, survivin levels were analyzed 
by Western blotting in PANC-1 and MIA PaCa-2 cells treated with gemcitabine or proton 
irradiation alone or with the sequential combinations described previously at 48 h post 
treatment (Figure 1).  Treatment of PANC-1 cells with gemcitabine or protons resulted in 
a 2 and 4 fold increase in survivin expression respectively (Figure 4C). 
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Figure 4 C & D. Detergent-solubilized extracts of (C) PANC-1 and (D) MIA PaCa-2 
cells treated with 10 Gy of proton radiation and 10 PM gemcitabine were analyzed at 48h 
for reactivity with antibodies for survivin and E-actin or GAPDH (loading control), by 
Western blotting. 
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Figure 4 E & F: (E) PANC-1 and (F) MIA PaCa-2 membranes were stripped and 
reprobed with antibodies for XIAP after which densitometric fold changes for each were 
indicated below.  Molecular-weight (Mr) markers in kilodaltons are shown on the left. 
 
 
 
 
73 
In contrast, treatment of MIA PaCa-2 cells only showed a 2 to 3 fold increase in 
those cells treated with protons.  Gemcitabine treatment for 48 h resulted in a down 
regulation of survivin protein (Figure 4D).  Both cell lines exhibited very little change in 
survivin protein expression from that of the control in the sequential combination 
treatments (Figure 4C, D).  XIAP has been known to interact more directly with the 
apoptotic pathway machinery than survivin 135.  Both cell lines also exhibited very little 
change in XIAP protein expression compared to control, with the noticeable exception of 
gemcitabine  →  proton  treatment  (Figure  4E,  F).    This  sequential  treatment  showed  a  
marked decrease in XIAP protein expression, which may be responsible for the MIA 
PaCa-2 cells being more susceptible to the combination of gemcitabine and proton 
irradiation then the PANC-1 cells. 
 
siRNA Knockdown of XIAP Further Potentiates Cell Death After 
Gemcitabine and Proton Combination Therapy 
To further investigate the role survivin and XIAP may play in proton radiation 
resistance of the PANC-1 cells, siRNA knockdown experiments were completed.  Three 
days after transfection with the siRNAs (described in Materials and Methods), cells were 
analyzed for the presence of Survivin and XIAP knockdown.  PCR analysis indicated that 
survivin and XIAP knockdown was successful (Figure 5A), with approximately 75% 
knockdown of XIAP and 40% knockdown of Survivin.  
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Figure 5.  Knockdown of the inhibitor of apoptosis proteins survivin and XIAP, using 
siRNA, increases drug and radiation killing of PANC-1 pancreatic cancer cells.  (A) 
Knockdown of survivin and XIAP expression.  PANC-1 cells were transfected with 
either Scrambled siRNA or siRNA designed to knockdown survivin or XIAP. 
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Furthermore, after 72h IAP knockdown, cells were treated with either gemcitabine, 
proton radiation, or 24h gemcitabine followed by proton radiation (Figure 1).  Forty-eight 
hours after treatment, cells were harvested for propidium iodide flow cytometric analysis.  
As hypothesized, the addition of the XIAP siRNA to the PANC-1 cells resulted in a 
marked increase in gemcitabine/proton-induced apoptosis compared to that recorded in 
the cells having survivin knockdown or those of the control (Figure 5B). 
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Figure 5B. (B) PANC-1 cells were first transfected with siRNA against either survivin or 
XIAP for 12 h after which they were treated using 10 Gy of proton radiation and 10 PM 
gemcitabine.  Cells were harvested and analyzed for DNA content by propidium iodide 
staining and flow cytometry at 48 hr.  Percentages of apoptotic cells with hypodiploid 
(sub-G1) DNA content as well as the polyploid are indicated per each condition tested. 
Data are the mean r SD of two independent experiments. 
 
 
 
 
 
77 
Discussion 
There has been little success in developing effective systemic therapies for the 
treatment of patients with locally advanced or metastatic pancreatic cancer.  
Chemotherapy was first combined with radiotherapy in the treatment of pancreatic cancer 
when clinicians at the Mayo Clinic in 1969 added 5-Fluorouracil (5-FU) to external beam 
radiotherapy.  The result was an improved mean survival of 10.4 months for the 
combination therapy compared to 6.3 months for those patients receiving radiotherapy 
alone 136,137.  As a result, this combination has been considered standard therapy for 
locally advanced pancreatic cancer 137 and though multiagent regimens which include 5-
FU have sought to improve upon this combination, randomized phase III trials have 
failed to confirm survival advantage over that with 5-FU alone 138.  More recently, the 
nucleoside analog gemcitabine provided encouraging results in both antitumor effects and 
its impact on parameters of clinical benefit for patients with pancreatic cancer such as, 
decreased pain severity, decreased requirement for opioid analgesics, increased appetite 
and weight gain 138.  In direct comparison on locally advanced pancreatic cancer and 
metastatic pancreatic cancer, gemcitabine treatment resulted in a 5.56 month overall 
survival compared to a 4.41 month overall survival using 5-FU.  In combination with 
conventional radiotherapy gemcitabine extended overall survival to 11.3 months 
compared to 5-FU extending it by 10.4 months 137,138.  As a result, gemcitabine has 
become widely accepted for unresectable pancreatic cancer. 
As pancreatic tumors are well advanced before detection, with survival reduced 
due to high rates of distant metastases, the continued use of conventional radiation-based 
therapies has been brought into question.  As tumor loads increase, superfluous radiation 
delivered to surrounding normal tissue leads to increasing treatment morbidity.  As a 
78 
result, better control of dose distribution and localization are necessary.  Proton 
radiotherapy allows for both.  Where local control is suboptimal with conventional 
photon radiotherapy, proton radiotherapy provides improved physical dose distribution, 
and improved localization to anatomic sites and histologies.  The resulting improvements 
to both dose distribution and localization will ultimately lead to dose escalation for 
anatomical sites where local control with conventional radiation dose has been 
suboptimal such as in advanced pancreatic disease 125,139. 
The aim of the current work was to define the involvement of survivin following 
chemotherapy and radiation therapy and to determine if proton irradiation followed 
classical radiation treatment observations.  Our data shows that proton irradiation alone 
exhibited similar results as has been reported in photon radiation treatment.  However, 
sequential treatment using gemcitabine before proton irradiation induced significant 
apoptotic cell death.  While survivin seems to be minimally involved in the mechanism of 
radioresistance, our work provides evidence that XIAP down regulation may be involved 
in the sensitization of MIA PaCa-2 cells and the concomitant radioresistance of PANC-1 
cells.  It has been demonstrated that RNAi-mediated knockdown of XIAP as well as 
small molecule inhibitors of XIAP sensitize pancreatic cancer cells to apoptosis via 
activation of caspases 2, 3, 8 and 9, and loss of mitochondrial membrane polarization 140.  
Furthermore, XIAP small molecule inhibitors have been shown to synergize the effects of 
radiation and gemcitabine alone 141.   
An important finding of these studies was the treatment of PANC-1 and MIA 
PaCa-2 cells with proton irradiation caused a significant number of the cells to become 
polyploid.  Polyploidy is a state in which cells possess more than two sets of homologous 
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chromosomes.  It is commonly believed that polyploid cells arise after cellular stress, 
ageing, and in various diseases, perhaps because polyploidy confers a metabolic benefit 
142-144.  Polyploid cells have been shown to be genetically unstable and can be the 
intermediates where aneuploid cells become cancerous 144.  In our hands, treatment of the 
pancreatic cancer cells lines with proton irradiation alone or before being combined with 
gemcitabine resulted in a significant enhanced polyploid fraction of cells (Figure 4).  The 
cells treated with gemcitabine alone or with gemcitabine followed by proton irradiation 
prohibited this polyploidy.  These findings suggest that proton irradiation-resistant 
pancreatic cells may gain enhanced genetic instability and ultimately a more aggressive 
tumor phenotype.  However, administering gemcitabine as a pretreatment to proton 
irradiation may reduce this genetic instability and ultimately allow the proton irradiation 
to result in a more effective killing of the tumor.  Furthermore, as polyploidy is a state of 
having more than two sets of chromosomes, survivin is a chromosomal passenger protein, 
and its deregulation in cancer promotes tetraploidy or aneuploidy, we strongly believe 
that by better understanding the role of gemcitabine and proton irradiation biology in 
regard to survivin expression modulation will provide useful data for the combining of 
therapies for the killing of radioresistant pancreatic cancer. 
XIAP, a unique and best-characterized member of the inhibitor of apoptosis (IAP) 
family, has been identified as a central regulator of caspase-dependent apoptosis.  
Whether the activation of apoptosis is initiated by events that perturb the mitochondria 
(via caspase-9) or progress directly from cell surface receptors (via caspase-8), the ability 
of XIAP to inhibit the downstream executioner caspases-3 and -7 makes it a potent and 
broad inhibitor of cell death145 and important target for therapy.  XIAP reduction has 
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been reported in cells treated with protons and hypoxia in three kinds of cancers: lung, 
hepatoma and leukemia146.  However, pancreatic cancers were not investigated.  A 
broadened search to include photon and UV radiation revealed that much work has been 
accomplished investigating radiation-induced downregulation of XIAP and the 
mechanisms whereby this happens.  A recent study describes UVB-induced sensitization 
coinciding with XIAP degradation which then allows for functional caspase 3-induced 
apoptosis147.  Furthermore, the loss of XIAP was shown to be the result of UVB-
enhanced Ikappa B alpha degradation, resulting in NF-kappaB-dependent transcriptional 
repression of XIAP147.  Future  studies  will  explore  XIAP’s  involvement  in  the  sequential  
chemo- and  radiosensitization  of  pancreatic  cancer  as  well  as  survivin’s  role  in  XIAP  
stabilization and the possibility of shifting the survival phenotype to apoptosis by 
interfering with this union. 
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CHAPTER FOUR 
DISCUSSION 
  
This work demonstrates a role for YY1 in the transcriptional regulation of 
survivin, an important target in cancer therapeutics.  Contrary to our initial hypothesis, 
YY1 was shown to downregulate survivin promoter activity.  The second part of this 
work shows that, at least in principle, decreased expression of IAPs such as survivin and 
XIAP through a combination of chemotherapy with proton radiotherapy may increase the 
sensitivity of tumors to cell death.  While the latter aspect of the dissertation has a clear 
implication in cancer therapy, the former aspect may draw criticism from the cancer 
biology community owing to its lack of application to the specific approaches to cancer 
treatment.  In the past this criticism may have been more relevant, but current approaches 
to cancer therapy are beginning to include transcription factors as very valid targets of 
cancer therapy.  As previously mentioned, Hanahan and Weinberg have produced 
seminal work summarizing the hallmarks of cancer 148.  These hallmarks include (1) 
evasion of programmed cell death, (2) insensitivity to growth-inhibitory signals, (3) 
limitless replicative potential, (4) sustained angiogenesis, (5) self-sufficiency in growth 
signals, and (6) tissue invasion and metastatic spread.  They more recently proposed two 
emerging hallmarks that include 1) evasion of immune destruction and 2) deregulation of 
cellular energetics 149.  A review by Mees et al. has eloquently summarized how a variety 
of transcription factors play direct roles in each of these hallmarks of cancer in hopes of 
furthering a shift in thinking that embraces targeting of transcription factors in cancer 
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therapy 150.  Among the many transcription factors discussed, several are worth noting in 
greater detail here given their relevance to survivin and YY1.  Table 3 summarizes 
several transcription factors with specific relevance to survivin and YY1. 
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Table 3:  Transcription Factors Involvement in Hallmarks of Cancer and Their 
Relationship to Survivin and YY1 (adapted from Mees et al. 150). 
Transcription Factor/Target Hallmark of Cancer Rationale 
NF-NB Sufficiency in growth 
signals 
Constiutively active in 
many cancers.  Positively 
regulates survivin 
transcription. 
Androgen receptor  Sufficiency in growth 
signals 
YY1 directly interacts with 
AR and enhances AR 
interaction with PSA 
promoter. 
Myc Insensitivity to growth-
inhibitory signals 
YY1 activates c-myc 
promoter 
p53 Evasion of programmed cell 
death 
Survivin downregulated by 
p53.  YY1 downregulates 
p53.   
HIF-1D Sustained angiogenesis Positively regulates survivin 
transcription 
Sp-1 Sustained 
angiogenesis/evasion of 
programmed cell death 
Transcriptional activator of 
survivin.  Interruption of 
Sp-1 binding to survivin 
promoter induces cell death 
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Therapeutic Potential of YY1 in Cancer Therapy 
The role of survivin in therapeutic approaches to cancer remains promising, as 
there are ongoing efforts to target it in new and innovative ways.  Although the role of 
YY1 in cancer has been known for a while now, efforts to exploit it for therapy are in 
their relative infancy.  Just as the role of YY1 in cancer biology is controversial, so is its 
value in therapeutic approaches to cancer.  In ovarian cancer patients, one group found a 
positive correlation between YY1 expression and response to taxane therapy.  In this 
study, YY1 knockdown lead to a significant reduction in cell proliferation and 
anchorage-independent growth as well as increased effectiveness of the drug paclitaxel 78.  
This is postulated to be because of positive regulation of genes involved in microtubule 
stabilizing activity.  TRAIL is a promising ligand for inducing cell death in clinical 
applications because it has been shown to induce anti-tumor activity while sparing 
nonmalignant tissue 151.  TRAIL induces cell death by binding to death receptors DR4 or 
DR5 with subsequent activation of caspases.  Baritaki et al. 152 showed that siRNA-
mediated knockdown of YY1 results in increased DR5 expression and sensitization to 
TRAIL-mediated apoptosis.  YY1 is capable of directly binding to the DR5 promoter to 
downregulate its expression 153.  They also show that treatment of prostate cancer cells 
(PC3) with the nitric oxide donor DETANONOate sensitizes cells to TRAIL-induced cell 
death by downregulating NF.B and downstream of that YY1.  The same group has 
shown that inhibition of the anti-apoptotic factor BCLXL is also involved, but it is 
unknown if this is via regulation of BCLXL by YY1.  This represents another line of 
evidence that interruption of YY1 activity has potential for sensitization of tumors to 
chemotherapy and other treatment modalities.  Given  the  controversy  as  to  YY1’s  role  in  
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cancer, this will result in significant challenges in understanding how to approach 
individual types of cancer therapy as it relates to inhibition of YY1.  This will require that 
targeting of YY1 be highly cancer specific to avoid dysregulation of YY1 in normal 
tissue. 
 
YY1 and Survivin: Beyond Transcriptional Regulation 
Tumor metastasis is the most common cause of death in cancer patients. It is a 
remarkably complex process with several several steps described by Hanahan and 
Weinberg that are required for a malignant cell to fully metastasize 148.  The first step is 
invasion, which involves the loss of cell adhesion molecules.  Without loss of surface 
adhesion molecules it is not possible for a cell to begin migration into neighboring tissue.  
The second step involves intravasation of the invading malignant cells into the blood or 
lymphatic system.  The third step, which only a small percent of intravasated cells are 
though to be able to accomplish, is extravasation through capillaries at a site distant to the 
primary tumor.  Once extravasated, cells must then regain adhesion molecules that allow 
the cell to establish the ability to survive in the new environment.  In carcinomas, the 
metastatic process is thought to consist of a number of distinct steps.  The complex 
mechanisms required to accomplish each of these steps are the subject of intense 
research. 
Epithelial-to-Mesenchymal Transition (EMT) is a proposed mechanism by which 
malignant cells initiate the need for a loss of adhesion molecules so that invasion can take 
place.  EMT is characterized by a loss of E-cadherin  and  β-catenin, and a gain in N-
cadherin and vimentin expression (reviewed by Huber et al. 154).  The transcription 
factors Twist, Snail, and Slug have been identified as the major regulators of these 
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adhesion molecules 155-157.  Research from our laboratory indicates that survivin is 
involved in the invasion step of metastasis 158.   
Survivin is overexpressed in primary tumors in addition to distant metastatic cells, 
however no direct involvement in the mechanism of metastasis has been identified.  Our 
lab has recently found a novel means by which survivin promotes cell invasion.  
Extracellular survivin is able to promote invasion of HeLa cells through a collagen 
matrix, and antibody depletion of survivin abrogates this increased cell invasion 158.  
Studies are ongoing to identify mechanisms behind this observation.  Very recently Yie et 
al. 159 found that patients with survivin-expressing circulating non-small cell lung cancer 
cells had a higher instance of cancer recurrence and increased follow-up lymph node 
involvement.  Other studies have shown that survivin is able to delineate node positive 
from node negative rectal cancer 160.  In small cell adencarcinoma of the lung, patients 
with histological evidence of high survivin expression had more evidence of veinous 
invasion of malignant cells, and overall patients with high survivin expression had 
decreased survival 161.  In squamous cell carcinomas, survivin expression correlates with 
high grade, poorly differentiated tumors and with increased lymph node metastasis 162.  A 
common theme in these studies is the presence of almost entirely correlative data with 
little or no mechanistic information.   
Among the many target genes of YY1 being discovered, some involved in 
metastasis are now being identified.  A report in 2005 hypothesized that cooperation of 
YY1 and AP-1 may increase the repression of the galactocerebrosidase (GALC) gene.  
GALC is an enzyme that is overexpressed on the surface of cancer cells.  Suppression of 
this enzyme leads to an accumulation of galactocerebroside, which results in a decrease 
90 
in cellular adhesion and inhibition of apoptosis.  This in turn leads to increased cell 
proliferation and migration 163.  This observation, although it was largely conjecture, was 
the first evidence that YY1 may be involved in cancer invasion and metastasis.  However, 
in the search to identify new genes involved in metastasis suppression, Wang et al. (2005) 
discovered that HLJ1, a metastasis suppressor, is positively regulated by YY1 164.  High 
levels of YY1 expression correlated with HLJ1 expression , and promoter reporter assays 
indicated that YY1 was acting directly on transcription of HLJ1.  Subsequent studies 
found that a synergistic relationship between YY1 and AP1 lead to a 5 times higher 
activation of HLJ1 and much more potent in vitro cancer cell invasion 165.  Using the 
osteosarcoma cell line SaOS-2, de Negris et al.64 found that deletion of YY1 leads to a 
decrease in cell invasion in vitro and decrease metastasis in vivo.  Deletion of YY1 also 
correlated with a decrease in vascular endothelial growth factor (VEGF) and 
angiogenesis.  They also identified a host of genes involved in cell motility, cell cycle, 
cell adhesion, angiogenesis, and signal transduction that exhibited significant changes 
when YY1 was deleted 64.  One report suggested that YY1 is a regulator of Snail, one of 
the key transcription factors responsible for regulation of EMT, a key feature of 
metastasis 166.  Together these  data  detail  the  complicated  nature  of  YY1’s  involvement  
in cancer metastasis, as it appears that in some types of cancer it may inhibit metastasis, 
while in others such as osteosarcoma it may promote metastasis and aggressiveness of the 
disease. 
 
Future Directions 
The work presented here illustrates a role for YY1 in survivin transcriptional 
repression in the osteosarcoma cell line U2OS.  However, the role of YY1 in 
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transcription of survivin in other cancer types has yet to be thoroughly investigated.  
Preliminary  evidence  from  our  laboratory  indicates  a  similar  repressive  role  for  YY1’s  
observed repression of survivin in the pancreatic cancer cell line Panc-1.  In Chapter 3, 
data was presented that indicated an important role for survivin expression levels in Panc-
1 radioresistance, but it suggested an even larger role for the inhibitor of apoptosis XIAP 
in the radioresistance of PANC-1 cells.  Therefore, future studies should broaden the 
investigation of cancer-specific YY1 regulation of survivin transcription and be expanded 
to investigation of transcriptional regulation of IAPs such as XIAP.   
 The work presented in Chapter 2 shows multiple avenues of evidence for the 
involvement of YY1 involvement in basal survivin transcription, but future efforts should 
attempt to identify the role of YY1 in cellular response to stresses in the form of 
chemotherapeutics, radiotherapy, or natural agent exposure.  HIF-1D’s  role  in  survivin  
transcriptional upregulation is now well established 30,31.  While YY1 is not clearly 
established as a stress-response transcriptional factor per se, several studies have 
indicated that is involved in unfolded protein response and resulting ER stress 167 and 
may even inhibit the function of p53 in response to genotoxic stress 168. 
 In  keeping  with  the  need  to  better  understand  YY1’s  role  in survivin-mediated 
cellular stress response, it is also critical for future studies to measure functional 
outcomes as a consequence of survivin transcriptional modulation.  Preliminary evidence 
in our lab indicates that YY1 overexpression in U2OS tet-off cells may be involved in 
enhanced cellular proliferation as measured by the Ki-67 assay (unpublished data).  
However, it is unknown the extent to which YY1 overexpression is specifically involved 
in this enhanced proliferation or if it is indeed mediated by survivin or by one of the other 
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numerous transcriptional targets of YY1.  The reporter data presented in Chapter 2 
indicates very robust repression of survivin promoter activity when YY1 is 
overexpressed, but much more moderate reduction in protein expression.  A recent study 
was able to show a role for YY1 in mammary cell proliferation, migration, clonogenicity, 
invasion, and tumor formation, and they identified YY1-mediated p27 degradation as a 
likely mechanism behind this 169.  In a similar fashion, future work should elucidate 
whether YY1 is able to modulate cellular invasion, migration, proliferation, and other 
outcomes through its regulation of survivin.  These studies will be critical to further 
efforts to establish new therapeutic approaches based on survivin targeting.    
Our lab has recently described a novel pool of survivin existing in the 
extracellular space 158.  Current studies are exploring ways in which this pool of survivin 
may contribute to disease in the normal neighboring cells in the tumor microenvironment.  
Antibody depletion of this extracellular pool of survivin may prove to be a valid 
therapeutic approach for solid tumors.  However, at this point the mechanism for export 
of survivin in unknown and under investigation.  If YY1 is indeed a modulator of 
survivin transcription, it stands to reason that YY1 overexpression or knockdown may 
alter the amount of survivin that is exported to the extracellular space.   
 
Summary and Conclusion 
Cancer is a disease that is increasingly being understood to be a constellation of 
hundreds if not thousands of different diseases.  This is likely why, despite a multitude of 
significant advances in our understanding of cancer, current therapies leave much to be 
desired in terms of patient health and well being.  The future of cancer therapy will 
hopefully include personalized approaches to individual disease, but this will require a 
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more complete understanding of the underlying factors involved in cancer development 
and advancement.  The work described in this dissertation will serve as a small, but 
perhaps important, addition to the body of knowledge regarding survivin transcription 
and the role of survivin and other IAPs in resistance to death induction by presently used 
chemotherapeutics and radiotherapy techniques.   
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